Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

Phase I/II Trial: BIBF 1120 Added to Low-dose Cytarabine in Elderly Patients With Acute Myeloid Leukemia (AML)

The recruitment status of this study is unknown because the information has not been verified recently.
Verified December 2013 by University Hospital Muenster.
Recruitment status was  Active, not recruiting
Boehringer Ingelheim
Information provided by (Responsible Party):
University Hospital Muenster Identifier:
First received: November 15, 2011
Last updated: December 10, 2013
Last verified: December 2013
No Study Results Posted on for this Study
  Study Status: This study is ongoing, but not recruiting participants.
  Estimated Study Completion Date: No date given
  Estimated Primary Completion Date: November 2014 (Final data collection date for primary outcome measure)